EntrepreneurialCheck
Nirmesh Patel estimated net worth profile

Nirmesh Patel Net Worth (Estimated)

Chief Scientific Officer at Cambridge Cancer Genomics · YC S17

est. wealth $19K IndianAsian

Quick answer

Nirmesh Patel's estimated net worth / paper wealth is $19K (range $13K–$28K) as of 2026.

Nirmesh Patel is Chief Scientific Officer at Cambridge Cancer Genomics (YC S17). Independent Entrepreneurial Check model estimate from public YC data.

At a glance

NameNirmesh Patel
RoleChief Scientific Officer
CompanyCambridge Cancer Genomics
YC batchS17
Est. company val$1.0M
Assumed ownership2%
Est. paper wealth / net worth$19K
$13K – $28K
  • Company status: Inactive
  • Background: Indian, Asian
  • Education: PhD in Oncology and Biomedical Sciences from the University of Cambridge
  • Region: United Kingdom
  • Industries: Healthcare, Diagnostics
  • Team size: 25
  • Website: http://ccg.ai

Who is Nirmesh Patel?

Nirmesh Patel is associated with Cambridge Cancer Genomics, a company focused on transforming cancer diagnostics through data-driven approaches.

Highlights:

  • University of Cambridge
  • Deloitte
  • Cambridge Cancer Genomics

Background

IndianAsian

Heritage labels inferred from name patterns only — not verified. Heritage/background labels may be inferred and are not verified identity documents.

About Cambridge Cancer Genomics

CCG.ai exist to ensure that each patient has the right drug, at the right time, to beat their cancer. ‍ We build the software to enable data-driven precision oncology and systematically develop data-driven biomarkers indicative of treatment response. We believe that increasing amounts of clinical and genomic data have the potential to transform cancer treatment, and enable oncologists to make smarter decisions...

Model inputs

FAQ: Nirmesh Patel net worth and Cambridge Cancer Genomics valuation

What is Nirmesh Patel's net worth?

Nirmesh Patel's estimated net worth / paper wealth is $19K (range $13K–$28K) as of 2026. Entrepreneurial Check publishes an independent model-based estimate from public company and role data.

Nirmesh Patel net worth

Nirmesh Patel's estimated net worth / paper wealth is $19K (range $13K–$28K) as of 2026. This Nirmesh Patel net worth figure is estimated paper wealth, not a verified statement of assets.

How much is Nirmesh Patel worth?

Nirmesh Patel's estimated net worth / paper wealth is $19K (range $13K–$28K) as of 2026. How much Nirmesh Patel is worth here means estimated paper wealth from public company and role data — not financial advice.

How rich is Nirmesh Patel?

Nirmesh Patel's estimated net worth / paper wealth is $19K (range $13K–$28K) as of 2026. “How rich is Nirmesh Patel” here means estimated paper wealth from public company and role data — not verified net worth or financial advice.

Nirmesh Patel fortune

Nirmesh Patel's estimated net worth / paper wealth is $19K (range $13K–$28K) as of 2026. This Nirmesh Patel fortune figure is estimated paper wealth only, not a verified statement of assets.

Nirmesh Patel equity value

Nirmesh Patel's estimated net worth / paper wealth is $19K (range $13K–$28K) as of 2026. Nirmesh Patel equity value on this page is modeled paper wealth from estimated ownership — not a disclosed cap table or verified net worth.

What is Cambridge Cancer Genomics valuation?

Cambridge Cancer Genomics's estimated valuation on Entrepreneurial Check is $1.0M. Independent model output, not a verified appraisal or official mark.

What is Cambridge Cancer Genomics post-money valuation?

Cambridge Cancer Genomics's estimated valuation on Entrepreneurial Check is $1.0M. That figure is a modeled post-money mark when a public raise is available — not a verified appraisal or official mark.

What is Cambridge Cancer Genomics funding?

Cambridge Cancer Genomics funding, when a public raise is available, is a model input on this Entrepreneurial Check profile. How much Cambridge Cancer Genomics raised is not a complete cap table — figures are estimates only.

How much did Cambridge Cancer Genomics raise?

How much Cambridge Cancer Genomics raised, when disclosed, informs the estimated Cambridge Cancer Genomics valuation and founder paper-wealth figures on this page. Independent estimate only — not a complete cap table or financial advice.

How much money did Cambridge Cancer Genomics raise?

How much money Cambridge Cancer Genomics raised, when a public figure is available, is a model input for the estimated Cambridge Cancer Genomics valuation on this profile. Estimates only — not a complete cap table.

What is Cambridge Cancer Genomics series funding?

Cambridge Cancer Genomics series funding, when a public raise is disclosed, informs the estimated Cambridge Cancer Genomics valuation here. Not a complete financing history.

What company is Nirmesh Patel building?

Nirmesh Patel is Chief Scientific Officer at Cambridge Cancer Genomics, a Y Combinator-backed startup (batch S17).

What does Cambridge Cancer Genomics do?

Cambridge Cancer Genomics — CCG.ai empowers clinicians to make personalised treatment strategies…

What YC batch is Nirmesh Patel from?

Nirmesh Patel is associated with Y Combinator batch S17.

Where did Nirmesh Patel go to school?

Public profiles associate Nirmesh Patel with PhD in Oncology and Biomedical Sciences from the University of Cambridge.

What other companies is Nirmesh Patel connected to?

Public associations for Nirmesh Patel include Deloitte, Cambridge Cancer Genomics.

Where is Nirmesh Patel based?

Public directory data lists Nirmesh Patel's region as United Kingdom.

What industry is Nirmesh Patel in?

Nirmesh Patel is listed under Healthcare, Diagnostics.

How big is Cambridge Cancer Genomics?

Public data lists Cambridge Cancer Genomics's team size as 25.

What is Cambridge Cancer Genomics's status?

Cambridge Cancer Genomics is listed as Inactive in public company data.

What else is notable about Nirmesh Patel?

University of Cambridge.

Is Entrepreneurial Check affiliated with Y Combinator?

No. Entrepreneurial Check is an independent informational site and is not affiliated with, endorsed by, or sponsored by Y Combinator or the profiled companies.